GSK’s Linerixibat Shows Promise for PBC Itch Relief

GlaxoSmithKline (GB:GSK) has released an update.

GlaxoSmithKline (GSK) has announced promising Phase III trial results for linerixibat, a potential treatment for severe itch caused by primary biliary cholangitis (PBC), a rare autoimmune liver disease. The trial showed significant improvement in itch symptoms over 24 weeks compared to a placebo, highlighting linerixibat’s potential as the first global therapy for this unmet need. With PBC affecting thousands globally, this development could significantly impact patients’ quality of life.

For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.